{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T16:12:35Z","timestamp":1781712755347,"version":"3.54.5"},"reference-count":77,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012217","name":"Xuzhou Medical University","doi-asserted-by":"publisher","award":["XYFM202328"],"award-info":[{"award-number":["XYFM202328"]}],"id":[{"id":"10.13039\/501100012217","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Science and Education Strengthening Medicine in the 14th Five-Yeal Plan, Huaguo Mountain, Lianyungang City"},{"name":"the First People's Hospital Lianyungang"},{"name":"Affiliated Hospital of Xuzhou Medical University"},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["SF2313"],"award-info":[{"award-number":["SF2313"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Municipal key R&D Plan (Social Development) of Science and Technology Project in Lianyungang City"},{"DOI":"10.13039\/501100004030","name":"Jiangsu Normal University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.beha.2025.101633","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T11:12:47Z","timestamp":1747307567000},"page":"101633","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Applications and prospects of molecularly targeted drugs combined with CAR-T cell therapy to treat multiple myeloma"],"prefix":"10.1016","volume":"38","author":[{"given":"Yan","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2025.101633_bib1","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"7","key":"10.1016\/j.beha.2025.101633_bib2","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s40265-021-01514-0","article-title":"Evolution of treatment paradigms in newly diagnosed multiple myeloma","volume":"81","author":"Elnair","year":"2021","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.beha.2025.101633_bib3","first-page":"164","article-title":"The management of relapsed and refractory multiple myeloma","volume":"37","author":"Gahvari","year":"2023","journal-title":"Oncology (Williston Park)"},{"issue":"2","key":"10.1016\/j.beha.2025.101633_bib4","first-page":"121","article-title":"Interpretation of multiple myeloma guidelines update (version 2, 2023) of National Comprehensive Cancer Network (NCCN)","volume":"22","author":"Tao Yi","year":"2023"},{"issue":"18","key":"10.1016\/j.beha.2025.101633_bib5","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.beha.2025.101633_bib6","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J Clin Investig"},{"issue":"11","key":"10.1016\/j.beha.2025.101633_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13112639","article-title":"CART-cell therapy: recent advances and new evidence in multiple myeloma","volume":"13","author":"Martino","year":"2021","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.beha.2025.101633_bib8","first-page":"1184","article-title":"CAR T-cell therapy for multiple myeloma: a clinical practice-oriented review","volume":"114","author":"Sadek","year":"2023","journal-title":"Clin Pharmacol Therapeut"},{"key":"10.1016\/j.beha.2025.101633_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101082","article-title":"Advances in molecular targeted drugs in combination with CAR-T cell therapy for hematologic malignancies","volume":"74","author":"Huang","year":"2024","journal-title":"Drug Resist Updates : Rev Commentaries Antimicrobial Anticancer Chemotherapy"},{"issue":"1","key":"10.1016\/j.beha.2025.101633_bib10","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1080\/07853890.2023.2186480","article-title":"Efficacy and safety of Venetoclax-based regimens in relapsed or refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials","volume":"55","author":"He","year":"2023","journal-title":"Ann Med"},{"issue":"23","key":"10.1016\/j.beha.2025.101633_bib11","doi-asserted-by":"crossref","first-page":"5290","DOI":"10.1182\/bloodadvances.2021004603","article-title":"Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed\/refractory multiple myeloma","volume":"5","author":"Wang","year":"2021","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.beha.2025.101633_bib12","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.beha.2025.101633_bib13","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2023","journal-title":"J Clin Oncol : Off J American Soc Clin Oncol"},{"issue":"1","key":"10.1016\/j.beha.2025.101633_bib14","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41408-023-00966-9","article-title":"GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review","volume":"14","author":"Rodriguez-Otero","year":"2024","journal-title":"Blood Cancer J"},{"issue":"13","key":"10.1016\/j.beha.2025.101633_bib15","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-Targeted CAR T cells for myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.beha.2025.101633_bib16","doi-asserted-by":"crossref","first-page":"e751","DOI":"10.1016\/S2352-3026(24)00176-5","article-title":"Anti-BCMA\/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial","volume":"11","author":"Zhou","year":"2024","journal-title":"The Lancet Haematology"},{"issue":"26","key":"10.1016\/j.beha.2025.101633_bib17","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1182\/blood-2017-04-778423","article-title":"SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes","volume":"130","author":"Gogishvili","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2025.101633_bib18","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41375-023-02065-x","article-title":"Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma","volume":"38","author":"Li","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2025.101633_bib19","first-page":"1","article-title":"Advances in CD19-targeting CAR-T cell therapies for multiple myeloma","author":"Steinhardt","year":"2024","journal-title":"Expet Opin Biol Ther"},{"issue":"20","key":"10.1016\/j.beha.2025.101633_bib20","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1200\/JCO.21.01676","article-title":"Long-term follow-up of combination of B-cell maturation antigen and CD19 chimeric antigen receptor T cells in multiple myeloma","volume":"40","author":"Wang","year":"2022","journal-title":"J Clin Oncol : Off J American Soc Clin Oncol"},{"issue":"1","key":"10.1016\/j.beha.2025.101633_bib21","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41392-023-01702-2","article-title":"Fc receptor-like 5 (FCRL5)-directed CAR-T cells exhibit antitumor activity against multiple myeloma","volume":"9","author":"Yu","year":"2024","journal-title":"Signal Transduct Targeted Ther"},{"issue":"24","key":"10.1016\/j.beha.2025.101633_bib22","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.18632\/oncotarget.26792","article-title":"Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma","volume":"10","author":"Sun","year":"2019","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.beha.2025.101633_bib23","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1111\/bjh.19896","article-title":"Are we there yet? CAR-T therapy in multiple myeloma","volume":"205","author":"Mirvis","year":"2024","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.beha.2025.101633_bib24","first-page":"275","article-title":"Chimeric antigen receptor T-cell therapy in multiple myeloma: a comprehensive review of current data and implications for clinical practice","volume":"73","author":"Parikh","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1016\/j.beha.2025.101633_bib25","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1115940","article-title":"Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells","volume":"5","author":"Ot\u00e1hal","year":"2016","journal-title":"OncoImmunology"},{"issue":"1","key":"10.1016\/j.beha.2025.101633_bib26","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1158\/1078-0432.CCR-17-0344","article-title":"Lenalidomide enhances the function of CS1 chimeric antigen receptor-redirected T cells against multiple myeloma","volume":"24","author":"Wang","year":"2018","journal-title":"Clin Cancer Res : Offi J American Assoc Cancer Res"},{"issue":"12","key":"10.1016\/j.beha.2025.101633_bib27","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1158\/1535-7163.MCT-18-1146","article-title":"Anti-B-cell maturation antigen chimeric antigen receptor T cell function against multiple myeloma is enhanced in the presence of lenalidomide","volume":"18","author":"Works","year":"2019","journal-title":"Mol Cancer Therapeut"},{"issue":"1","key":"10.1016\/j.beha.2025.101633_bib28","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00262-021-02959-8","article-title":"Lenalidomide enhances the efficacy of anti-BCMA CAR-T treatment in relapsed\/refractory multiple myeloma: a case report and revies of the literature","volume":"71","author":"Zhao","year":"2022","journal-title":"Cancer Immunol Immunother : CII"},{"issue":"1","key":"10.1016\/j.beha.2025.101633_bib29","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1186\/s12967-024-05772-w","article-title":"BCMA CAR-T therapy combined with pomalidomide is a safe and effective treatment for relapsed\/refractory multiple myeloma","volume":"22","author":"Yan","year":"2024","journal-title":"J Transl Med"},{"issue":"4","key":"10.1016\/j.beha.2025.101633_bib30","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrd.2016.253","article-title":"From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors","volume":"16","author":"Ashkenazi","year":"2017","journal-title":"Nat Rev Drug Discov"},{"issue":"14","key":"10.1016\/j.beha.2025.101633_bib31","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.1182\/blood-2010-11-317438","article-title":"ABT-737 is highly effective against molecular subgroups of multiple myeloma","volume":"118","author":"Bodet","year":"2011","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2025.101633_bib32","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1158\/2159-8290.CD-21-1026","article-title":"Modulation of BCL-2 in both T cells and tumor cells to enhance chimeric antigen receptor T-cell immunotherapy against cancer","volume":"12","author":"Lee","year":"2022","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.beha.2025.101633_bib33","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.1038\/s41467-019-12321-3","article-title":"CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity","volume":"10","author":"Fu","year":"2019","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.beha.2025.101633_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20061283","article-title":"Killing mechanisms of chimeric antigen receptor (CAR) T cells","volume":"20","author":"Benmebarek","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"19","key":"10.1016\/j.beha.2025.101633_bib35","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1182\/bloodadvances.2020004146","article-title":"Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed\/refractory multiple myeloma","volume":"5","author":"Costa","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.beha.2025.101633_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2023.122096","article-title":"Anti-BCMA surface engineered biomimetic photothermal nanomissile enhances multiple myeloma cell apoptosis and overcomes the disturbance of NF-\u03baB signaling in vivo","volume":"297","author":"Xiao","year":"2023","journal-title":"Biomaterials"},{"issue":"5","key":"10.1016\/j.beha.2025.101633_bib37","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.3324\/haematol.2022.282031","article-title":"Pirtobrutinib and venetoclax combination overcomes resistance to targeted and chimeric antigen receptor T-cell therapy in aggressive mantle cell lymphoma","volume":"108","author":"Liu","year":"2023","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.beha.2025.101633_bib38","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.molonc.2007.01.001","article-title":"The role of histone deacetylases (HDACs) in human cancer","volume":"1","author":"Ropero","year":"2007","journal-title":"Mol Oncol"},{"issue":"9","key":"10.1016\/j.beha.2025.101633_bib39","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd4360","article-title":"Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders","volume":"13","author":"Falkenberg","year":"2014","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"10.1016\/j.beha.2025.101633_bib40","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood-2012-06-438002","article-title":"Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia","volume":"121","author":"Haso","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2025.101633_bib41","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s40164-024-00507-5","article-title":"Exploring the role of histone deacetylase and histone deacetylase inhibitors in the context of multiple myeloma: mechanisms, therapeutic implications, and future perspectives","volume":"13","author":"Pu","year":"2024","journal-title":"Exp Hematol Oncol"},{"issue":"4","key":"10.1016\/j.beha.2025.101633_bib42","doi-asserted-by":"crossref","first-page":"737","DOI":"10.4049\/jimmunol.2300475","article-title":"Histone deacetylase inhibitors directly modulate T cell gene expression and signaling and promote development of effector-exhausted T cells in murine tumors","volume":"212","author":"Ibrahim","year":"2024","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.beha.2025.101633_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114065","article-title":"Class I HDAC inhibitors enhance antitumor efficacy and persistence of CAR-T cells by activation of the Wnt pathway","volume":"43","author":"Zhu","year":"2024","journal-title":"Cell Rep"},{"issue":"5","key":"10.1016\/j.beha.2025.101633_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/jpm11050334","article-title":"Targeted therapies for multiple myeloma","volume":"11","author":"Leow","year":"2021","journal-title":"J Personalized Med"},{"issue":"1","key":"10.1016\/j.beha.2025.101633_bib45","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41392-022-00915-1","article-title":"Identification of NOXA as a pivotal regulator of resistance to CAR T-cell therapy in B-cell malignancies","volume":"7","author":"Yan","year":"2022","journal-title":"Signal Transduct Targeted Ther"},{"issue":"10","key":"10.1016\/j.beha.2025.101633_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2020.153114","article-title":"Immune checkpoint inhibitors in multiple myeloma: a review of the literature","volume":"216","author":"Caserta","year":"2020","journal-title":"Pathol Res Pract"},{"issue":"2","key":"10.1016\/j.beha.2025.101633_bib47","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1158\/2643-3230.BCD-21-0181","article-title":"Blockade or deletion of IFN\u03b3 reduces macrophage activation without compromising CAR T-cell function in hematologic malignancies","volume":"3","author":"Bailey","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"10","key":"10.1016\/j.beha.2025.101633_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2023.09.001","article-title":"Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells","volume":"56","author":"Agarwal","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.beha.2025.101633_bib49","article-title":"PD-1 disrupted CAR-T cells in the treatment of solid tumors: promises and challenges","volume":"121","author":"Mcgowan","year":"2020","journal-title":"Biomed Pharmacotherapy = Biomed Pharmacotherapie"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101633_bib50","doi-asserted-by":"crossref","first-page":"9925","DOI":"10.1182\/blood-2022-168734","article-title":"Nivolumab-Based salvage therapy to restore T cell fitness in penta-refractory multiple myeloma with relapse to anti-BCMA CAR T cell therapy","volume":"140","author":"Waldschmidt","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2025.101633_bib51","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008429","article-title":"PD-1 downregulation enhances CAR-T cell antitumor efficiency by preserving a cell memory phenotype and reducing exhaustion","volume":"12","author":"Ouyang","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"11","key":"10.1016\/j.beha.2025.101633_bib52","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1038\/s41375-020-0958-y","article-title":"Targeting nuclear import and export in hematological malignancies","volume":"34","author":"Nachmias","year":"2020","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.beha.2025.101633_bib53","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s11523-020-00758-2","article-title":"Targeting nuclear export proteins in multiple myeloma therapy","volume":"15","author":"Theodoropoulos","year":"2020","journal-title":"Targeted Oncol"},{"issue":"7","key":"10.1016\/j.beha.2025.101633_bib54","doi-asserted-by":"crossref","first-page":"e526","DOI":"10.1016\/j.clml.2022.01.014","article-title":"Guidance for use and dosing of selinexor in multiple myeloma in 2021: consensus from international myeloma foundation expert roundtable","volume":"22","author":"Nooka","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.beha.2025.101633_bib55","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/leu.2013.115","article-title":"CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications","volume":"28","author":"Tai","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2025.101633_bib56","doi-asserted-by":"crossref","DOI":"10.1177\/20406207231219442","article-title":"Treatment of multiple myeloma with selinexor: a review","volume":"15","author":"Huang","year":"2024","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.beha.2025.101633_bib57","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1182\/blood-2024-207202","article-title":"Selinexor reduces the immunosuppressive properties of macrophages and synergizes with CD19 CAR-T cells against B-cell lymphoma","volume":"144","author":"Wenjing Luo","year":"2024","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2025.101633_bib58","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1111\/bjh.16550","article-title":"Selinexor-based regimens for the treatment of myeloma refractory to chimeric antigen receptor T cell therapy","volume":"189","author":"Chari","year":"2020","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.beha.2025.101633_bib59","doi-asserted-by":"crossref","DOI":"10.3892\/or.2021.8121","article-title":"Combining selective inhibitors of nuclear export (SINEs) with chimeric antigen receptor (CAR) T cells for CD19-positive malignancies","volume":"46","author":"Wang","year":"2021","journal-title":"Oncol Rep"},{"issue":"13","key":"10.1016\/j.beha.2025.101633_bib60","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1182\/bloodadvances.2020002346","article-title":"Navigating the narrow bridge to CAR T-cell therapy","volume":"4","author":"Yang","year":"2020","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.beha.2025.101633_bib61","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/nrd4204","article-title":"PI3K and cancer: lessons, challenges and opportunities","volume":"13","author":"Fruman","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.beha.2025.101633_bib62","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.874325","article-title":"Inhibiting PI3K-AKT-mTOR signaling in multiple myeloma-associated mesenchymal stem cells impedes the proliferation of multiple myeloma cells","volume":"12","author":"Heinemann","year":"2022","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.beha.2025.101633_bib63","doi-asserted-by":"crossref","first-page":"639","DOI":"10.2217\/14796694.3.6.639","article-title":"PI3 kinase\/AKT pathway as a therapeutic target in multiple myeloma","volume":"3","author":"Harvey","year":"2007","journal-title":"Future Oncol"},{"issue":"4","key":"10.1016\/j.beha.2025.101633_bib64","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1182\/blood.2021011597","article-title":"PI3K\u03b4\/\u03b3 inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity","volume":"139","author":"Funk","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101633_bib65","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1182\/blood-2020-140410","article-title":"Updated results from the phase I CRB-402 study of anti-Bcma CAR-T cell therapy bb21217 in patients with relapsed and refractory multiple myeloma: correlation of expansion and duration of response with T cell phenotypes","volume":"136","author":"Alsina","year":"2020","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2025.101633_bib66","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1002\/eji.201948455","article-title":"Ex vivo blockade of PI3K gamma or delta signaling enhances the antitumor potency of adoptively transferred CD8+ T cells","volume":"50","author":"Dwyer","year":"2020","journal-title":"Eur J Immunol"},{"issue":"6","key":"10.1016\/j.beha.2025.101633_bib67","doi-asserted-by":"crossref","DOI":"10.3390\/cells11060941","article-title":"Biological hallmarks and emerging strategies to target STAT3 signaling in multiple myeloma","volume":"11","author":"Zhou","year":"2022","journal-title":"Cells"},{"issue":"14","key":"10.1016\/j.beha.2025.101633_bib68","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1182\/blood-2016-10-745059","article-title":"Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma","volume":"129","author":"Gupta","year":"2017","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2025.101633_bib69","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/s41577-023-00856-y","article-title":"Targeting IL-6 trans-signalling: past, present and future prospects","volume":"23","author":"Rose-John","year":"2023","journal-title":"Nat Rev Immunol"},{"issue":"23","key":"10.1016\/j.beha.2025.101633_bib70","doi-asserted-by":"crossref","first-page":"6299","DOI":"10.1158\/1078-0432.CCR-20-1739","article-title":"Itacitinib (INCB039110), a JAK1 inhibitor, reduces cytokines associated with cytokine release syndrome induced by CAR T-cell therapy","volume":"26","author":"Huarte","year":"2020","journal-title":"Clin Cancer Res : Offi J American Assoc Cancer Res"},{"key":"10.1016\/j.beha.2025.101633_bib71","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.bbrc.2022.01.070","article-title":"Ruxolitinib reduces severe CRS response by suspending CAR-T cell function instead of damaging CAR-T cells","volume":"595","author":"Xu","year":"2022","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"10.1016\/j.beha.2025.101633_bib72","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/imm.13416","article-title":"The role of Bruton's tyrosine kinase in the immune system and disease","volume":"164","author":"Mcdonald","year":"2021","journal-title":"Immunology"},{"key":"10.1016\/j.beha.2025.101633_bib73","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.leukres.2017.02.005","article-title":"Bone marrow mesenchymal stem cells regulate stemness of multiple myeloma cell lines via BTK signaling pathway","volume":"57","author":"Zhao","year":"2017","journal-title":"Leuk Res"},{"issue":"11","key":"10.1016\/j.beha.2025.101633_bib74","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22115707","article-title":"Bruton's tyrosine kinase targeting in multiple myeloma","volume":"22","author":"Von Suskil","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"7","key":"10.1016\/j.beha.2025.101633_bib75","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.jcyt.2023.03.005","article-title":"Bruton tyrosine kinase inhibitors preserve anti-CD19 chimeric antigen receptor T-cell functionality and reprogram tumor micro-environment in B-cell lymphoma","volume":"25","author":"Luo","year":"2023","journal-title":"Cytotherapy"},{"key":"10.1016\/j.beha.2025.101633_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2024.103350","article-title":"Advances in chimeric antigen receptor T cell therapy for autoimmune and autoinflammatory diseases and their complications","volume":"150","author":"Zeng","year":"2025","journal-title":"J Autoimmun"},{"key":"10.1016\/j.beha.2025.101633_bib77","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.1182\/blood-2023-186888","article-title":"Efficacy and safety of chimeric antigen receptor T cells therapy strategy with dual targeting of CD19 and CD70 to treat relapsed\/refractory diffuse large B-cell lymphoma","volume":"142","author":"Tu","year":"2023","journal-title":"Blood"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692625000386?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692625000386?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T20:39:37Z","timestamp":1762547977000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692625000386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":77,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1521692625000386"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2025.101633","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Applications and prospects of molecularly targeted drugs combined with CAR-T cell therapy to treat multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2025.101633","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101633"}}